Vanguard Capital Management
GANX icon

Vanguard Capital Management’s Gain Therapeutics GANX Stock Holding History

Vanguard Capital Management’s Portfolio GANX Stock Details GANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$975K Buy
480,269
+80,383
+20% +$148K ﹤0.01% 3599
2026
Q1 		$776K Buy
+399,886
New +$870K ﹤0.01% 3600

Other funds holding GANX

Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
PCM
Potomac Capital Management New York $147M AUM
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
DCM
DME Capital Management New York $3.91B AUM 36.1% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Capital Management's GANX Position: Q2 2026 in Review

Vanguard Capital Management increased its Gain Therapeutics (GANX) stake by 20% in Q2 2026, buying an estimated $148K and bringing the position to 480,269 shares worth $975K. The position accounts for ﹤0.01% of the portfolio, ranked #3599.

Vanguard Capital Management first reported a position in GANX in Q1 2026 and has held it in 2 quarters since. 50 funds tracked by Wall St. Rank hold GANX as of Q2 2026.

  • Vanguard Capital Management held 480,269 shares of Gain Therapeutics worth $975K as of Q2 2026.
  • Vanguard Capital Management bought 80,383 Gain Therapeutics shares in Q2 2026, an estimated $148K.
  • Gain Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3599 holding.
  • Vanguard Capital Management first reported a position in Gain Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 50 funds tracked by Wall St. Rank held Gain Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.